Tag Archives: antibodies

Pregnant people who get COVID-19 may pass antibodies along to babies

  • A new study found that 87% of new mothers who had detectable COVID-19 antibodies shared them with their newborns through the umbilical cord.
  • The find suggests it’s possible that newborn babies can confer some protective COVID-19 immunity from a mother’s infection during pregnancy.
  • It also raises questions about whether vaccinating pregnant people might help protect their babies from infections after birth.
  • Visit Business Insider’s homepage for more stories.

Pregnant people who get COVID-19 may pass some disease-fighting benefits along to their babies, a new study published Friday in the journal JAMA Pediatrics suggests.

The study measured COVID-19 antibodies in 83 new mothers at a Pennsylvania hospital last year, and found 87% of their newborns developed measurable antibodies in their umbilical cords. The antibodies popped up both in the cords of babies whose mothers had coronavirus symptoms, and those who had none. 

That doesn’t necessarily mean that newborns whose mothers have had COVID-19 will be immune to the novel coronavirus, but it is a sign that they could have some form of protection against future infections, especially during their first months of life.

The study also found that people who’d had COVID-19 earlier on in their pregnancy had a better chance of transferring antibodies across the placenta to their fetus. This aligns with what we know about how long it can take a person’s body to develop antibodies after any coronavirus infection: typically, at least 1-3 weeks.

The study raises questions about whether vaccinating pregnant women against COVID-19 could help protect their newborns

Nurses care for a newborn at Diaconesses Hospital in Paris on November 17, 2020.

Martin Bureau/AFP via Getty Images


Given that it’s possible that mothers who’ve had COVID could pass on some level of viral protection to their babies, it’s also possible that “maternal vaccination could do the same,” Dr. Flor Munoz, an infectious disease expert from Baylor College of Medicine, said in an editorial that accompanied the study’s release on Friday.

Maternal vaccination during pregnancy is already how many newborns are temporarily protected from other dangerous but vaccine-preventable diseases, including influenza, and whooping cough.

It’s not clear yet if that would be the case with COVID-19, but it’s an important question to consider, given that there are no coronavirus vaccines authorized for babies or children so far.

Munoz suggested that “maternal vaccination starting in the early second trimester” might be the best time, in order to help protect the baby as well as the mother from future infection.

“The timing of maternal vaccination to protect the infant, as opposed to the mother alone, would necessitate an adequate interval from vaccination to delivery (of at least 4 weeks),” Munoz added.

Data on pregnant women and COVID-19 vaccines are scarce



A health worker administers a dose of the Pfizer-BioNtech COVID-19 vaccine to a pregnant woman at Clalit Health Services, in Tel Aviv on January 23, 2021.

Jack Guez/AFP via Getty Images


Because pregnant people were intentionally left out of many COVID-19 vaccine trials, there’s still not enough data to definitively rule coronavirus vaccines are safe for expectant mothers.

“There is no data that suggests these vaccines cause harm in pregnant women — but there just isn’t a lot of data,” immunologist Scott Hensley, who co-authored the study, told The Philadelphia Inquirer.

Both the US Centers for Disease Control and the American College of Obstetricians and Gynecologists (ACOG) say if pregnant women want a vaccine, and are in a priority position to get one (i.e. healthcare workers, teachers), they should feel free to go ahead.

Dr. Mark Turrentine, a member of the COVID-19 expert group at the ACOG told the New York Times this new study shows how important it is to include more pregnant women in future vaccine trials, “particularly when the benefit of vaccination is greater than the potential risk of a life-threatening disease.”

Pregnant people who contract COVID-19 are at slightly greater risk of developing severe and fatal coronavirus infections. If you’re pregnant and wondering whether you should take a coronavirus vaccine, talk to your doctor or vaccine administrator about it.

Loading Something is loading.



Read original article here

Babies get Covid-19 antibodies from mothers while in the womb, study finds

The findings also suggest that vaccinating pregnant women might protect their unborn babies, as well, the researchers said — and it’s worth studying the possibility. Pregnant women are advised to get influenza vaccines to protect both themselves and their babies.

Newborn specialist Dr. Dustin Flannery of Children’s Hospital of Philadelphia and colleagues studied more than 1,400 mothers and newborns. They found that protective IgG antibodies were transferred across the placenta in 72 out of 83 infected or previously infected pregnant women they studied.

None of the babies of infected mothers developed coronavirus infection. And 60% of the women who had antibodies to coronavirus had no symptoms, the researchers reported.

“Could maternal antibodies help delay the onset of infection or protect the infant from becoming infected, having severe disease, or dying of COVID-19?” asked Dr. Flor Munoz, a molecular virologist at the Baylor College of Medicine, who was not involved in the research.

Newborns are vulnerable to infection, and any protection would be welcome, Munoz wrote in an accompanying commentary. But it’s also known that antibodies against other viruses, such as influenza or tetanus, wear off quickly when passed from mother to infant during pregnancy, so it would be important to study when and how to vaccinate infants, Munoz said.

The US Centers for Disease Control and Prevention recommends immunizing babies against the flu at six months, for instance, even if the mothers were vaccinated during pregnancy.

“To what extent can antibodies transferred through breast milk protect lactating newborns?” Munoz asked.

“Should infants be vaccinated regardless of maternal infection, and if so, what is the best timing to initiate infant vaccines? Is there a potential detrimental effect of maternal antibodies on infant responses to active immunization? And what would be the optimal vaccine and vaccination regimen for infants, considering their risk and unique immunologic needs?”

Read original article here

Monoclonal antibodies benefit high-risk COVID-19 patients

CLOSE

The first COVID case in the U.S. was found in January, 2020. One year later, the numbers surrounding the pandemic are alarming.

USA TODAY

While vaccines may help slow the COVID-19 pandemic over the next months, drug company Eli Lilly announced Tuesday that its treatments can help save lives in the meantime. 

The company’s drug bamlanivimab was authorized by the U.S. Food and Drug Administration late last year and has been used by 125,000 high-risk patients nationwide based on early-stage data suggesting it could be effective.  

The drug is a monoclonal antibody, meaning it mimics one of the natural antibodies the immune system uses to fight off the virus.

Former President Donald Trump as well as former New Jersey Gov. Chris Christie and former New York City Mayor Rudy Giuliani all received monoclonal antibodies shortly after they were diagnosed with COVID-19.

In a large, late-stage study the company unveiled Tuesday, bamlanivimab combined with another monoclonal antibody, etesevimab, was found to be extremely effective in high-risk patients diagnosed with COVID-19.

Among patients who received a placebo, 10% of those at high risk ended up in the hospital, compared to just 2% of those who received the drug cocktail – a 70% drop. Patients were diagnosed an average of four days before treatment.

Trump touted monoclonal antibodies: Why aren’t more people getting them?

None of the 518 patients who got the cocktail died, compared to eight deaths among an equal-sized group of people with COVID-19 who received a placebo. 

The single drug and the cocktail performed equally well, said Lilly’s chief scientific officer Dr. Daniel Skovronsky, but the company is going to switch to making the combination once it receives FDA authorization.

The combination is more likely to remain effective, he said at an afternoon news conference, as the virus that causes COVID-19 evolves, leading to new variants.

“Bamlanivimab alone is predicted to be effective against more than 99% of all strains that we see in the United States today,” he said. “Bamlanivimab plus etesevimab should take care of the rest of them.”

The company may also add a third or fourth monoclonal as needed in the future to manage any variants that escape the current two-drug combination, he said.

An earlier Lilly study also showed that bamlanivimab can reduce serious disease among nursing home residents at high risk for COVID-19 and in the early days after infection.  

In future trials, Lilly will compare its proposed treatments against this combination, Skovronsky said, rather than against a placebo. Because the combination is so effective, it would be unethical to give high-risk patients a placebo, he said. 

There are 100,000 doses of bamlanivimab available today to patients around the world and another 250,000 will become available by the end of the quarter, Skovronsky said. 

Is it too little, too late? US officials urge Americans to ask their doctors about monoclonal antibodies for COVID

The U.S. government has bought hundreds of thousands of doses of Lilly’s and another combination antibody from Regeneron.

But many doses remain on shelves, unused, because of the difficulties of providing the drug to patients. 

To get a benefit, people have to receive the drug within the early stages of disease – once hospitalized with COVID-19, the drug does nothing to help, a Lilly study has shown.

Patients may not learn about the drugs until it’s too late, though.

At an early stage of the disease, people are particularly contagious, and hospitals, overrun with COVID-19 patients, have had a hard time making the time and space to deliver monoclonal antibodies. The drugs are delivered via infusion, like chemotherapy, rather than through a quick injection.

Skovronsky said Lilly is trying to speed up the time it takes to deliver the infusion and has gotten it down to under 20 minutes from an hour, which should make it easier to deliver. 

Finally, several physicians’ groups, including the Infectious Disease Society of America, have not recommended the drugs in their treatment guidelines, citing a lack of definitive evidence. Skovronsky said he hopes the new data will be enough to convince doctors to recommend monoclonal antibodies to their high-risk COVID-19 patients.

The company’s future studies will focus on testing whether smaller doses can help extend the predicted supply of the two monoclonal antibodies. It won’t be easy to produce more drug, said Lilly chairman and CEO David Ricks, but the drug that is made can be stretched further if lower doses can be used.

The recent studies tested 2,800 mg of each of the two monoclonals, and earlier studies had examined doses as high as 7,000 mg. But if only 700 mg can produce nearly as much benefit, the available supply will go much further, he said.

“A dose that could spread the available supply by a factor of two, three, or four to have the maximum human impact – that’s what we need to do now,” Ricks said. 

For more information about bamlanivimab in the U.S., Lilly has set up a 24-hour support line at 1-855-545-5921. Patients and physicians can also visit covid.infusioncenter.org or the HHS Therapeutic Distribution locator to find a potential treatment location.

Contact Karen Weintraub at kweintraub@usatoday.com.

Health and patient safety coverage at USA TODAY is made possible in part by a grant from the Masimo Foundation for Ethics, Innovation and Competition in Healthcare. The Masimo Foundation does not provide editorial input.

Autoplay

Show Thumbnails

Show Captions

Last SlideNext Slide

Read or Share this story: https://www.usatoday.com/story/news/health/2021/01/26/eli-lilly-monoclonal-antibodies-high-risk-covid-19-patients-coronavirus/4263087001/

Read original article here

The Ultimate News Site